Teva Pharmaceutical Industries (TEVA.TA) Osake Kurssi

Teva Pharmaceutical Industries Ltd is primarily active in the pharmaceutical industry.

The main competitors of Teva Pharmaceutical Industries Ltd in the market include companies such as Pfizer, Novartis, Mylan, Johnson & Johnson, and GlaxoSmithKline. These companies also operate in the pharmaceutical industry and compete with Teva in areas such as generic drugs, specialty pharmaceuticals, and innovative health solutions.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company. Founded in 1901, Teva has a rich history and impressive background. Originally established in Jerusalem, Israel, Teva has grown to become the world's largest manufacturer of generic drugs. With a global network of research and development centers, manufacturing sites, and commercial operations in over 60 countries, Teva is committed to improving health and increasing access to high-quality healthcare solutions worldwide. The company has a diverse portfolio of products, spanning multiple therapeutic areas, including specialty medicines, generic drugs, and over-the-counter products. Teva's dedication to innovation, quality, and affordability has made it a trusted name in the pharmaceutical industry.

Teva Pharmaceutical Industries Ltd has achieved significant milestones throughout its history. The company became the largest generic drug manufacturer in the world, offering affordable healthcare solutions to millions of patients worldwide. Teva's acquisition of Actavis Generics further enhanced its global market presence. It pioneered the development of cutting-edge medications and continues to drive innovation in the pharmaceutical industry. Teva's commitment to quality and patient-centric approach have earned it numerous recognitions and awards, solidifying its position as a leader in the market. With a dedicated focus on improving people's lives through accessible medicines, Teva Pharmaceutical Industries Ltd stands as a prominent player in the healthcare sector.

Teva Pharmaceutical Industries Ltd is primarily present in various countries and regions globally. Some key regions include North America, Europe, Asia Pacific, Latin America, and the Middle East. In North America, Teva has a significant presence in the United States and Canada. In Europe, the company operates in countries such as Germany, France, Spain, Italy, and the United Kingdom. Teva also has a strong presence in countries like China, Japan, India, Australia, and South Korea, among others, in the Asia Pacific region. Moreover, Teva Pharmaceutical Industries Ltd has expanded its reach to Latin American countries like Brazil and Mexico, as well as the Middle East region.

Teva Pharmaceutical Industries Ltd represents values of integrity, quality, and accessibility in the pharmaceutical industry. With a strong corporate philosophy focused on making a positive impact on global health, Teva strives to provide affordable and innovative healthcare solutions to people around the world. By prioritizing patient needs, Teva emphasizes ethical business practices and promotes sustainable growth. As a leading global pharmaceutical company, Teva's commitment to improving and saving lives is evident in its extensive product portfolio, research initiatives, and dedication to making healthcare accessible to all.

Analyytikot asettavat tällä hetkellä Teva Pharmaceutical Industries-osakkeelle keskimääräisen tavoitehinnan 10,82 USD (mediaani: 10,82 USD), mikä merkitsee −74,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 7 analyytikkoarvioon.

Teva Pharmaceutical Industries Analyytikkojen kursstavoitteet 2026

7 analyytikkoa arvioi tällä hetkellä Teva Pharmaceutical Industries-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Teva Pharmaceutical Industries-yhtiöltä 16,75 Mrd. USD liikevaihtoa ja 2,03 USD osakekohtaista tulosta.

Teva Pharmaceutical Industries Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Teva Pharmaceutical Industries-osake noteerataan hintaan 37,38 EUR (41,72 USD).

Teva Pharmaceutical Industries Ltd is one of the largest and most well-known pharmaceutical companies worldwide. The company is based in Israel and employs over 45,000 people around the world. It operates in various divisions and offers a wide range of products. The company's divisions include generics, specialty pharmaceuticals, and biopharmaceuticals. In the generics division, Teva offers a variety of generic medications that are available at an affordable price. These medications are essentially copies of brand-name drugs that are already on the market. Teva also operates in the specialty pharmaceuticals division. Here, the company focuses on the development and marketing of medications for rare diseases. These medications treat diseases where there are either no treatment options or where existing treatments are ineffective. The company is also active in the biopharmaceuticals division, where it focuses on the development and marketing of biologics. Biologics are medications made from living organisms. They are used to treat diseases such as cancer, arthritis, and multiple sclerosis. Some of Teva's products include Copaxone, Azilect, Qvar, ProAir, and NuvaRing. Copaxone is a medication for the treatment of multiple sclerosis and is Teva's top-selling drug. Azilect is used to treat Parkinson's disease. Qvar and ProAir are asthma medications, and NuvaRing is a hormonal contraceptive. Teva's business model is based on the development and marketing of pharmaceutical products to improve people's health. The company generates revenue through the sale of its products. Teva is a major player in the generic market and has a significant market share in this division. The company also has a strong presence in the specialty pharmaceuticals market. Teva also utilizes partnerships and acquisitions to expand its business and enter new markets. An important acquisition for Teva was the acquisition of Actavis Generics, which made Teva one of the largest generic pharmaceutical companies in the world. Overall, Teva Pharmaceutical Industries Ltd is a leading pharmaceutical company that offers a wide range of products and operates in various divisions. The company has a strong presence in the generic market and also focuses on the development of medications for rare diseases and biopharmaceuticals. Teva is expected to continue to grow and enter new markets through partnerships and acquisitions.

odotettu liikevaihto Teva Pharmaceutical Industries on 16,75 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Teva Pharmaceutical Industries on 2,38 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Teva Pharmaceutical Industries:n hinta-voitto-suhde (P/E) on tällä hetkellä 20,54. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Teva Pharmaceutical Industries-osakkeen arvostusta.

Teva Pharmaceutical Industries:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,92. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Teva Pharmaceutical Industries-osakkeen arvostuskennuslukuna.

Teva Pharmaceutical Industries:n Eulpool-laatuscore on 5/10.

Teva Pharmaceutical Industries:n ISIN on IL0006290147. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Teva Pharmaceutical Industries:n WKN on 906517. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Teva Pharmaceutical Industries:n ticker on TEVA.TA. Tämä pörssinoteeraus käytetään Teva Pharmaceutical Industries-osakkeiden kauppaan pörssissä.